Market Overview - On July 24, the Shanghai Composite Index rose by 0.65% to 3605.73 points, with the Shenzhen Component Index increasing by 1.21%, and the ChiNext Index up by 1.5% [1] - The total trading volume in A-shares was 1.87 trillion yuan, slightly down from 1.9 trillion yuan the previous day [1] - The market showed a low open and high close, with sectors like vaccines and medical beauty experiencing significant gains, particularly the vaccine ETF (159643) which surged by 6.33% in a single day [1][3] Vaccine Sector Analysis - As of July 22, five districts in Foshan reported confirmed cases of Chikungunya virus, totaling 3195 cases, prompting a warning from the World Health Organization about the risk of widespread outbreaks [4] - Bavarian Nordic's Chikungunya vaccine (VIMKUNYA) has been approved in Europe and the U.S., showing a neutralizing antibody response rate of 97.8% after a single dose, marking it as the first effective vaccine against this virus [4] - The domestic vaccine sector has been under pressure since the decline in COVID-19 demand, with the National Vaccine and Biotechnology Index down over 60% from its 2022 peak, leading to low institutional holdings [4] Short-term Industry Outlook - The vaccine industry is currently in a bottoming phase, with overall vaccine batch issuance down 14% year-on-year in Q1 2025, reflecting inventory adjustments and weak self-paid demand [5] - Companies are focusing on pipeline adjustments, emphasizing technological innovation and the development of multi-valent vaccines, particularly in the oncology vaccine sector, which is gaining traction [5] - The upcoming mid-year performance disclosures of relevant companies will be critical to monitor for price pressures and operational efficiency improvements [7] Long-term Growth Drivers - The long-term growth drivers for the vaccine industry remain clear, supported by policy changes, technological advancements, and increasing global demand [6] - The mRNA technology platform is advancing rapidly, with potential applications in respiratory viruses and oncology vaccines, while new products like the shingles vaccine and RSV vaccine could enhance market protection [8] - The aging population and heightened health awareness are expected to drive adult vaccine demand, with significant gaps in vaccination rates for diseases like shingles and HPV [9] Investment Opportunities - The vaccine ETF (159643) tracks the vaccine biotechnology index, which includes companies involved in vaccine research, production, and related biotech services, reflecting the overall performance of the vaccine sector [9]

Group 1: Company Performance - Baike Bio reported a revenue of approximately 1.229 billion RMB for 2024, a year-on-year decline of 32.64% [1] - The net profit attributable to shareholders was around 232 million RMB, down 53.67% year-on-year [1] - The decline in performance is primarily attributed to reduced sales of the shingles vaccine [1] Group 2: Green Bamboo Bio's Situation - Green Bamboo Bio's stock price fell by 9.09% on May 2, leading to significant sell-offs, with a trading volume of 1.8036 million shares, the highest since 2024 [2] - The company has experienced a drastic decline in liquidity, with 10 months in the past 17 months having a monthly trading volume of less than 200,000 shares [2] - Green Bamboo Bio's market capitalization is currently around 4.1 billion HKD, below the 7 billion HKD threshold required for inclusion in the Hang Seng Index [4] Group 3: Financials of Green Bamboo Bio - Green Bamboo Bio reported a net loss of 168 million RMB for the year, a reduction of 32.5% compared to the previous year's loss of 249 million RMB [4] - The company has not yet commercialized any products, with total revenue remaining at zero [4] - Research and development expenses decreased by 21.7% to 135 million RMB [4] Group 4: Product Development - Green Bamboo Bio's core product, the recombinant shingles vaccine LZ901, has completed Phase III clinical enrollment and submitted a Biologics License Application (BLA) [6] - LZ901 is expected to be the first shingles vaccine with a tetrameric molecular structure, targeting adults aged 50 and above [6] - The vaccine is positioned to compete with GSK's Shingrix, which has seen significant sales growth, reaching 3.446 billion GBP in 2023 [8] Group 5: Market Dynamics - The domestic vaccine industry is facing structural adjustment pressures, with a decline in consumer willingness to receive vaccinations and a significant drop in demand for self-paid vaccines [10] - The competition in the vaccine market is intense, with over 10 manufacturers competing in areas like rabies and influenza vaccines [10] - The market for shingles vaccines is currently less competitive, with only Baike Bio's Ganwei and GSK's Shingrix available, providing an opportunity for LZ901 if it commercializes as expected [10] Group 6: Challenges Ahead - Despite the potential of LZ901, the company may struggle to significantly improve its financial structure and fundamentals due to market education challenges and profit margin pressures [11] - The current vaccination rate for shingles in China is only 0.1%, significantly lower than in developed countries, indicating a need for market education [10]